Source:http://linkedlifedata.com/resource/pubmed/id/12485205
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
10
|
pubmed:dateCreated |
2002-12-17
|
pubmed:abstractText |
The present study describes the preclinical pharmacology of a highly selective 5-HT1D receptor agonist PNU-142633. PNU-142633 binds with a Ki of 6 nm at the human 5-HT1D receptor and a Ki of> 18 000 nm at the human 5-HT1B receptor. The intrinsic activity of PNU-142633 at the human 5-HT1D receptor was determined to be 70% that of 5-HT in a cytosensor cell-based assay compared with 84% for that of sumatriptan. PNU-142633 was equally effective as sumatriptan and a half-log more potent than sumatriptan in preventing plasma protein extravasation induced by electrical stimulation of the trigeminal ganglion. Like sumatriptan, PNU-142633 reduced the increase in cat nucleus trigeminal caudalis blood flow elicited by electrical stimulation of the trigeminal ganglion compared with the vehicle control. The direct vasoconstrictor potential of PNU-142633 was evaluated in vascular beds. Sumatriptan increased vascular resistance in carotid, meningeal and coronary arteries while PNU-142633 failed to alter resistance in these vascular beds. These data are discussed in relation to the clinical findings of PNU-142633 in a phase II acute migraine study.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Analgesics,
http://linkedlifedata.com/resource/pubmed/chemical/Chromans,
http://linkedlifedata.com/resource/pubmed/chemical/PNU 142633F,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, Serotonin, 5-HT1D,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Serotonin,
http://linkedlifedata.com/resource/pubmed/chemical/Serotonin Receptor Agonists,
http://linkedlifedata.com/resource/pubmed/chemical/Sumatriptan
|
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
0333-1024
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
22
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
799-806
|
pubmed:dateRevised |
2010-11-18
|
pubmed:meshHeading |
pubmed-meshheading:12485205-Analgesics,
pubmed-meshheading:12485205-Animals,
pubmed-meshheading:12485205-CHO Cells,
pubmed-meshheading:12485205-Cardiovascular System,
pubmed-meshheading:12485205-Cats,
pubmed-meshheading:12485205-Chromans,
pubmed-meshheading:12485205-Cricetinae,
pubmed-meshheading:12485205-Dogs,
pubmed-meshheading:12485205-Drug Evaluation, Preclinical,
pubmed-meshheading:12485205-Female,
pubmed-meshheading:12485205-Guinea Pigs,
pubmed-meshheading:12485205-Humans,
pubmed-meshheading:12485205-Male,
pubmed-meshheading:12485205-Migraine Disorders,
pubmed-meshheading:12485205-Receptor, Serotonin, 5-HT1D,
pubmed-meshheading:12485205-Receptors, Serotonin,
pubmed-meshheading:12485205-Serotonin Receptor Agonists,
pubmed-meshheading:12485205-Sumatriptan
|
pubmed:year |
2002
|
pubmed:articleTitle |
Preclinical studies characterizing the anti-migraine and cardiovascular effects of the selective 5-HT1D receptor agonist PNU-142633.
|
pubmed:affiliation |
Department of Neurobiology and Structural, Analytical and Medicinal Chemistry, Pharmacia Corporation, Kalamazoo, MI 49001, USA. robert.b.mcall@pharmacia.com
|
pubmed:publicationType |
Journal Article,
Comparative Study
|